ArriVent BioPharma (AVBP) EBIT (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of EBIT data on file, last reported at -$46.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT rose 30.94% year-over-year to -$46.1 million; the trailing twelve-month figure through Mar 2026 stood at -$156.9 million (down 11.73% YoY), and the FY2025 full-year result was -$177.5 million, down 88.25% from the prior year.
• EBIT declined to -$46.1 million in Q1 2026, from -$38.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$12.2 million in Q1 2023 to a low of -$66.8 million in Q1 2025.
• A 4-year average of -$30.2 million and a median of -$24.2 million in 2024 frame the typical range for EBIT.
• Across the five-year window, EBIT tumbled 222.98% in 2025 and jumped 30.94% in 2026, its largest moves.
• Tracing AVBP's EBIT over 4 years: stood at -$23.1 million in 2023, then decreased by 2.54% to -$23.7 million in 2024, then tumbled by 63.78% to -$38.8 million in 2025, then decreased by 18.77% to -$46.1 million in 2026.
• Business Quant data shows AVBP's EBIT at -$46.1 million in Q1 2026, -$38.8 million in Q4 2025, and -$38.3 million in Q3 2025.